Prescribing Vortioxetine

Why Vortioxetine Matters (and Where the Hype Ends)

Vortioxetine is the most pharmacologically interesting antidepressant to come to market in the last generation, a multimodal serotonin modulator that touches six different serotonin targets, and also one of the most oversold. If you strip away the marketing, the honest summary is this: for core depressive symptoms it is no more effective than a generic SSRI, but it carries two genuine, clinically usable advantages, a lower burden of sexual dysfunction (especially at 5 to 10 mg) and a small but real signal for processing-speed cognition, at the cost of dose-limiting nausea and a brand-name price.

That is not nothing. Sexual dysfunction and the "brain fog" of depression are two of the most common reasons patients abandon otherwise-effective antidepressants, and vortioxetine gives you a targeted tool for exactly those patients. But it is not a smarter, stronger, or broadly better antidepressant, and prescribing it as though it were will waste money and disappoint patients.

A note on the name: it launched in September 2013 as Brintellix, then was renamed Trintellix in 2016 (an FDA safety alert in 2015 had flagged dangerous confusion with the antiplatelet drug Brilinta, ticagrelor). The molecule never changed.

Part 1: Indications: Who Is Vortioxetine For?

FDA-Approved Use

• Major Depressive Disorder in adults (approved 2013)

That is the entire approved label. Notably, vortioxetine sought and was denied an FDA indication for the "cognitive dysfunction of MDD" (2016 advisory panel): the benefit was judged too narrow and of uncertain clinical meaning. The label does mention cognitive symptoms of depression, but there is no standalone cognition indication.

Where It Genuinely Earns Its Place

Depression with prominent cognitive complaints. This is vortioxetine's signature niche. Depression impairs attention, memory, and processing speed to a degree one study equated with roughly 24 hours of sleep deprivation, and "diminished ability to think or concentrate" is a formal DSM-5 criterion. Vortioxetine improved the Digit Symbol Substitution Test (DSST), a two-minute measure of processing speed and attention, in 3 of 5 industry RCTs (n≈1,813) and did so consistently better than duloxetine. Crucially, path analysis suggests roughly 76% of the cognitive benefit is independent of mood improvement (vs. roughly 50% for duloxetine), implying a direct pro-cognitive action rather than "the depression just got better."

Depression where sexual dysfunction is the dealbreaker. The second real niche. In the pivotal switch trial (Jacobsen 2015), 447 patients with SSRI-induced sexual dysfunction were switched to vortioxetine (10 to 20 mg) or escitalopram (10 to 20 mg); vortioxetine produced significantly greater improvement in sexual functioning (CSFQ +8.8 vs +6.6, p=0.01), with an NNT of about 12 for sexual-function recovery. For a patient who got mood benefit from an SSRI but quit over sexual side effects, vortioxetine is a rational switch target.

Geriatric depression. Efficacy comparable to duloxetine in older adults, and in the one geriatric head-to-head, only vortioxetine (not duloxetine) improved the DSST, a potential edge when late-life depression comes bundled with cognitive slowing.

Patients with a history of antidepressant discontinuation syndrome. Because of its very long half-life (about 66 hours) and multimodal profile, vortioxetine has minimal discontinuation syndrome, a genuine advantage for the patient burned by paroxetine or venlafaxine withdrawal.

Emerging / Off-Label (Thin Evidence, Know the Ceiling)

• Adjunctive for schizophrenia negative symptoms: one 78-patient trial (add-on to risperidone, 20 mg/day) showed a large effect (0.97) on negative symptoms over 8 weeks, no effect on positive symptoms (Moazen-Zadeh 2020). Intriguing, single-study, not practice-changing.
• Age-related cognitive decline in non-depressed elderly: 100 patients over 65 with subthreshold cognitive complaints; vortioxetine plus computerized cognitive training beat placebo at 3 months (effect size 0.6). Promising, needs replication.

Where It Fails: Don't Reach for It Here

• Treatment-resistant depression: never properly studied for TRD; did not beat duloxetine or sertraline head-to-head. The one flattering TRD-ish result (70% vs 56% response vs agomelatine) used a single-failure definition, a non-standard comparator, and was never replicated. No established role as a switch/augmentation strategy.
• Generalized anxiety disorder as a primary target: one positive study, then three failed RCTs; pooled effect size a trivial 0.12, remission no better than placebo. Anxiety improves only insofar as the depression does.
• Adult ADHD: failed a 3-month RCT (Biederman 2019), despite the cognitive marketing.
• Binge-eating disorder: failed a small RCT (Grant 2019).

Part 2: Before You Start

Vortioxetine is refreshingly low-maintenance on the front end, one of its genuine practical virtues.

• No mandatory baseline labs.
• No baseline or periodic ECG: no QT-prolongation signal, no cardiac monitoring required (contrast citalopram).
• No metabolic monitoring driven by the drug itself; it is weight-neutral.

What is worth doing before you start:

• Document a baseline of the two things you're actually treating with this drug: mood and cognitive complaints (ask specifically about processing speed, concentration, word-finding), plus sexual function if that's the reason you're choosing it. If you'll want to claim a benefit later, measure it now: an ASEX or CSFQ for sexual function takes two minutes.
• Confirm no MAOI within the prior 14 days (and don't start an MAOI until about 14 days after stopping vortioxetine); serotonin-syndrome risk.
• Screen for bipolarity, as with any antidepressant, before monotherapy.
• Ask about strong CYP2D6 inhibitors already on board (bupropion, fluoxetine, paroxetine, quinidine); they change your dosing ceiling (see Interactions).

Who Is a Poor Candidate?

• Patients who cannot tolerate GI side effects, or for whom nausea would be especially destabilizing.
• Cost-sensitive patients when a generic SSRI/SNRI would do; the honest first question with vortioxetine is often, "is there a specific reason not to use a generic?"
• MAOI use within 14 days (absolute).

Part 3: How to Start and Dose

Formulation

Oral tablets: 5, 10, and 20 mg. Once-daily dosing, with or without food, though taking it with food or a snack meaningfully reduces the nausea and is the single most useful practical tip for getting patients to a therapeutic dose.

Starting Dose and Titration

• Start: 5 mg once daily (with food). Some prescribers start at 10 mg in younger, robust patients, but 5 mg first is gentler on the gut and costs you little time.
• Titrate: 5 mg → 10 mg → target 20 mg/day, as tolerated, generally allowing about a week or more between steps. There's no rush; antidepressant response takes weeks regardless.
• Maximum approved: 20 mg/day.

The Clinical Reality of Dosing

Here is where the label and the exam room diverge. Nausea is dose-dependent and frequently dose-limiting, so a large share of patients never comfortably reach 20 mg. As one expert (Gitlin) put it: "the GI side effects have precluded my ability to get to 20 mg with regularity, so I have a number of people at 5 or 10 mg."

Serotonin Transporter Occupancy by Dose (the Mechanistic Key to the Whole Drug)

This single table explains vortioxetine's personality: at 5 to 10 mg it sits below the roughly 80% SERT occupancy where classic serotonergic side effects (notably sexual dysfunction) take off, which is precisely why it spares sexual function at low-to-mid doses and loses that edge as you climb toward 20 mg.

Maintenance

• Most patients stabilize clinically at 5 to 10 mg.
• A 52-week open-label study found doses as low as 2.5 to 10 mg/day effective for relapse prevention. You do not need to be at 20 mg to keep someone well.

Part 4: Monitoring

Blessedly simple:

• No routine labs. No ECG. No blood pressure monitoring (unlike the SNRIs). No weight/metabolic panel driven by the drug.
• Do reassess the things you're targeting. At follow-up, re-ask about mood, cognitive symptoms, sexual function, and GI tolerance. If you chose vortioxetine for cognition, remember the cognitive-decline data required about 3 months to show effect; don't declare failure on the cognitive front too early.
• Standard antidepressant vigilance: monitor for emergent suicidality (boxed warning applies), activation/mania, and, as with any serotonergic, serotonin syndrome if combined with other serotonergic agents.

Part 5: Side Effects and How to Manage Them

The governing principle here is different from most antidepressants: vortioxetine's problem is not sedation, weight, or cardiac risk, it's the gut. GI intolerance is the reason patients quit or can't titrate.

Gastrointestinal (the Main Event)

Nausea is the most common and most dose-limiting side effect, reported in roughly 20 to 30% (about 25%) of patients, dose-dependent, and the single biggest obstacle to reaching 20 mg. Vomiting, diarrhea, and constipation (dose-dependent, notably at or above 20 mg) also occur. In head-to-head class data, vortioxetine ranks among the worst antidepressants for nausea (OR ~4.3, comparable to duloxetine).

Management:

• Take with food or a snack: the most effective single measure.
• Titrate slowly: hold at 5 mg longer, advance only when the gut settles.
• Nausea often attenuates over the first weeks; counsel patients to push through the early period if they can.
• For persistent nausea, an antiemetic such as ondansetron can bridge the titration (no tardive-dyskinesia risk, unlike dopamine antagonists).
• If GI intolerance is truly dose-limiting, stay at the tolerated dose: 5 to 10 mg still treats depression and still spares sexual function.

Sexual Function (the Selling Point, and It's Dose-Dependent)

This is where vortioxetine is genuinely differentiated, but be precise about the claim:

• At 5 to 10 mg: treatment-emergent sexual dysfunction is essentially non-inferior to placebo, the real advantage.
• At 15 to 20 mg: rates climb toward other antidepressants; pooled data show roughly 43 to 46% (vs about 32% placebo), numerically higher but not statistically significantly so, and still lower than duloxetine's roughly 48% (which was significantly above placebo).
• Switching an SSRI patient with sexual dysfunction to vortioxetine improves sexual function (NNT ~12 vs escitalopram).

Weight and Metabolic

Weight-neutral. Negligible weight gain in trials, a real advantage over mirtazapine, and better than several SSRIs/SNRIs. No adverse lipid or glucose signal attributable to the drug.

CNS / Neuropsychiatric

• Headache and dizziness: common, usually mild and transient.
• No sedation reported; the drug is not sedating and not markedly activating.
• Standard antidepressant class effects apply: monitor for emergent suicidality, and for activation/switch in undiagnosed bipolar patients.

Cardiac

• No QT prolongation, no ECG changes. One of the cleaner cardiac profiles in the antidepressant world, useful in cardiac patients where citalopram/escitalopram give pause.

Part 6: Overdose, Toxicity, and Boxed Warning

• Overdose: data are limited, but vortioxetine appears relatively benign in overdose. The main concern is serotonin syndrome, particularly in combination with other serotonergic drugs. No specific antidote; management is supportive.
• No cardiac lethality signal (no QT effect), distinguishing it favorably from tricyclics and citalopram in overdose.

Part 7: Drug Interactions

Vortioxetine is a substrate, not a major inhibitor, so it's cleaner than fluoxetine/paroxetine/fluvoxamine for polypharmacy, but its own levels can be pushed around.

Pharmacokinetic: What Changes Vortioxetine's Level

• Metabolized primarily by CYP2D6 (with CYP3A4 secondary). This has two consequences:
  • Strong CYP2D6 inhibitors (bupropion, fluoxetine, paroxetine, quinidine) raise vortioxetine levels. With a strong 2D6 inhibitor on board, or in a known CYP2D6 poor metabolizer, the practical move is to cap the dose (commonly at 10 mg) and watch tolerability.
  • Strong CYP inducers (rifampin, carbamazepine, phenytoin) can lower levels; a dose increase may be needed if co-prescribed.
• Vortioxetine itself does not meaningfully inhibit CYP enzymes, a genuine advantage over the 2D6-inhibiting SSRIs when the patient is on tamoxifen, tricyclics, beta-blockers, antipsychotics, or opioids.

Pharmacodynamic: Serotonergic Additivity

• MAOIs: contraindicated together; 14-day washout in each direction.
• Other serotonergics (SSRIs/SNRIs, tramadol, triptans, linezolid, methylene blue, St. John's wort): additive serotonin-syndrome risk; combine cautiously and counsel patients.
• Bleeding risk: as a serotonergic agent it can weakly impair platelet aggregation; watch with NSAIDs, anticoagulants, and antiplatelets.
• CNS depressants / alcohol: additive effects; counsel.

Part 8: Special Populations

Pregnancy

Human data are limited (historically FDA Pregnancy Category C, before the categories were retired). There is no strong signal of teratogenicity, but the evidence base is far thinner than for sertraline, which remains the go-to when an SSRI in pregnancy is acceptable. As with all late-third-trimester antidepressant exposure, watch the neonate for transient adaptation/discontinuation symptoms and, with any serotonergic, the small PPHN consideration. In practice: reserve vortioxetine in pregnancy for a woman who specifically needs this drug's profile and did poorly on better-studied agents; it's rarely a first choice for a newly pregnant patient.

Lactation

Data are sparse. Most authorities favor better-characterized agents (sertraline) for breastfeeding. If vortioxetine is continued, monitor the infant clinically.

Elderly (65 and Older)

• Efficacy comparable to duloxetine; a possible cognitive edge (DSST) in this group.
• Start low (5 mg), go slow, as with any antidepressant in older adults, and watch GI tolerance.
• No age-specific mandatory dose cap, but polypharmacy and CYP2D6 interactions matter more here.

Renal and Hepatic Impairment

• No dose adjustment is generally required for mild-to-moderate renal or hepatic impairment or across the usual severity range, a practical advantage, and unlike duloxetine (hepatic cautions) or the SNRIs (renal/BP concerns).
• Data in severe impairment are limited; use standard caution.

Pediatric

• Not FDA-approved under 18; no established pediatric efficacy. Off-label use is not supported by the evidence here.

Part 9: Discontinuation

This is a quiet advantage. Thanks to its roughly 66-hour half-life and multimodal profile, vortioxetine has minimal discontinuation syndrome, among the lowest in the antidepressant world, comparable in spirit to fluoxetine's long-half-life protection.

• For short courses, it can often be stopped without an elaborate taper.
• For longer-term use, a modest taper (for example, over one to two weeks, stepping down 20 → 10 → 5 mg) is still sensible and comfortable, but abrupt cessation is far better tolerated than with paroxetine, venlafaxine, or duloxetine.
• This makes vortioxetine a rational choice for the patient with a history of bad SSRI/SNRI withdrawal.

Part 10: Vortioxetine vs the Alternatives

Efficacy for core depression is a wash across the modern antidepressants: an industry meta-analysis (Llorca 2014) concluded vortioxetine is no more effective than other antidepressants, and in head-to-heads it did not beat duloxetine, venlafaxine, or sertraline on mood. So selection is a side-effect and niche decision:

• vs SSRIs (generic): similar mood efficacy; vortioxetine's edge is less sexual dysfunction at 5 to 10 mg and a DSST cognitive signal SSRIs don't have (SSRIs were neutral-to-negative on DSST across 9 prior trials). SSRIs win decisively on cost and familiarity. Reach for vortioxetine when the SSRI's sexual or cognitive downside is the specific problem.
• vs Duloxetine: duloxetine is at least as effective (arguably better) for mood, but vortioxetine reliably beats it on DSST and has less sexual dysfunction and no hepatic-with-alcohol caution. For medically complex patients, some experts prefer desvenlafaxine over either.
• vs Bupropion: if the goals are sexual sparing, cognition/energy, and weight, bupropion arguably does all three at least as well and much cheaper (no sexual dysfunction at all, activating, weight-neutral-to-loss, some cognitive data). Bupropion's downsides are anxiety/insomnia activation and seizure-threshold caution. For a patient whose main issue is sexual side effects, bupropion is often the better and cheaper first move; vortioxetine is the serotonergic alternative when you still want serotonergic coverage (for example, prominent anxiety).
• vs Vilazodone (the other "SPARI"): similar marketing (SERT inhibition plus 5-HT1A agonism), but vilazodone lacks vortioxetine's cognitive data, and its claimed faster-onset/anti-anxiety advantages were never substantiated.
• vs Mirtazapine / Trazodone: those are your choices when insomnia, appetite loss, or sedation is the target. Vortioxetine is the opposite profile: non-sedating, weight-neutral.

Why it's underused for the right reasons and overused for the wrong ones: the branded cost and frequent nausea rightly keep it off the first-line default; but its two real advantages (low-dose sexual sparing, processing-speed cognition) are underused precisely by clinicians who wrote it off entirely. Match it to the patient.

Mechanism: The Short Version

Vortioxetine is a multimodal serotonin modulator ("serotonin modulator and stimulator"), not a plain SSRI. It combines:

• Serotonin reuptake inhibition (SERT): the primary, SSRI-like action (50/65/80% occupancy at 5/10/20 mg)
• 5-HT1A agonism: thought to contribute to sexual sparing and to antidepressant effect
• 5-HT1B partial agonism
• 5-HT1D antagonism
• 5-HT3 antagonism: but note this doesn't spare the gut; nausea is still common
• 5-HT7 antagonism: the receptor most implicated in the pro-cognitive effects (learning/memory in animal models)

Preclinically it induces neurogenesis in mice, a plausible (unconfirmed-in-humans) substrate for the cognitive signal. Pharmacokinetically it has a long roughly 66-hour half-life (hence once-daily dosing and mild discontinuation), and is cleared mainly by CYP2D6 with CYP3A4 secondary. The multi-receptor profile is the reason it "doesn't feel like an SSRI": more GI upset, less sexual dysfunction at low dose, and a cognitive edge no pure SSRI matches.

The Bedside Cheat Sheet